| Name | Title | Contact Details |
|---|
Hazel Hawkins Memorial Hospital's new Ambulatory Surgery Center offers cutting edge technology that is ahead of all other hospitals in the Bay Area and the Monterey Bay Peninsula.
ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders. ACADIA has a pipeline of product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson’s disease psychosis. Pimavanserin is also in Phase II development for Alzheimer’s disease psychosis and has successfully completed a Phase II trial as a co-therapy for schizophrenia. ACADIA also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinson’s disease and other neurological disorders. All product candidates are small molecules that emanate from internal discoveries. ACADIA maintains a website at www.acadia-pharm.com to which ACADIA regularly posts copies of its press releases as well as additional information and through which interested parties can subscribe to receive e-mail alerts.
Biography Identity is a Bellingham, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DecisionLine Clinical Research is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Adheris is a Burlington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.